Buy Aczone

Aczone

What is Aczone?

Aczone is a prescription-only medication marketed in the United Kingdom for the treatment of acne vulgaris. The active ingredient in Aczone is dapsone, a synthetic sulfone that has anti-inflammatory and antibacterial properties. Aczone is supplied as a 100 mg oral tablet (pill) and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is intended for adults and adolescents with moderate inflammatory acne when other topical treatments have proven insufficient.

How Aczone Works in the Body

Dapsone’s therapeutic effect in acne results from two main actions:

• Anti-inflammatory activity - Dapsone inhibits the migration of neutrophils and reduces the release of inflammatory mediators such as interleukin-8. This dampens the inflammatory response that contributes to the formation of papules and pustules.
• Antibacterial effect - Dapsone interferes with bacterial synthesis of folic acid, limiting the growth of Propionibacterium acnes (now called Cutibacterium acnes), a key organism in acne development.

After oral ingestion, dapsone is rapidly absorbed, reaching peak plasma concentrations within 2-4 hours. It is extensively metabolised in the liver (acetylation and hydroxylation) and the metabolites are eliminated mainly via the kidneys. The drug’s half-life is approximately 20-30 hours, which supports once-daily dosing.

Conditions Treated by Aczone

Aczone is approved by the MHRA for the treatment of moderate inflammatory acne in patients aged 12 years and older. The medication is especially useful for lesions that are resistant to conventional topical therapies, such as benzoyl peroxide or topical antibiotics. It is not indicated for severe cystic acne, non-inflammatory comedonal acne, or for acne in very young children.

Who Should Not Use Aczone?

Absolute Contraindications

• Known hypersensitivity to dapsone or any sulfone-type medication.
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency - patients with this enzymatic defect are at high risk of hemolytic anemia when exposed to dapsone.
• Severe anemia or a history of methemoglobinemia.
• Pregnancy (category B in the UK) - dapsone should be avoided unless the clinical benefit clearly outweighs potential risk to the fetus.

Relative Contraindications

• Moderate to severe renal impairment (creatinine clearance < 30 mL/min) - dose adjustment may be required.
• Significant hepatic disease (e.g., Child-Pugh class C) - impaired metabolism can raise plasma levels.
• Concurrent use of other agents known to cause hemolysis (e.g., sulfonamides, primaquine).
• Elderly patients - may be more susceptible to adverse hematologic effects; start at the standard dose but monitor closely.

Special Populations

• Pregnancy and lactation - discuss risks with a healthcare professional; breastfeeding is not recommended while taking dapsone.
• G6PD deficiency testing - a screening test should be performed before initiating therapy.
• Elderly - consider baseline complete blood count (CBC) and liver function tests, then monitor periodically.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Dry skin or mild skin irritation
• Nausea, abdominal discomfort
• Headache
• Mild dizziness
• Transient darkening of urine (a harmless discoloration)

These effects are usually mild and resolve without medical intervention. Taking the tablet with food can reduce gastrointestinal discomfort.

Serious Adverse Events

• Hemolytic anemia - sudden drop in red blood cell count, presenting with fatigue, pallor, or dark urine.
• Methemoglobinemia - reduced oxygen-carrying capacity of blood; symptoms include cyanosis, shortness of breath, and chocolate-brown blood.
• Agranulocytosis - severe reduction in white blood cells, increasing infection risk; presents with fever, sore throat, or mouth ulcers.
• Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) - rare but require immediate medical attention.

If any of these serious symptoms develop, seek urgent medical care.

Drug Interactions

• Sulfonamide antibiotics (e.g., trimethoprim-sulfamethoxazole) - may increase risk of hemolysis.
• Primaquine and other antimalarials - additive hemolytic potential in G6PD-deficient individuals.
• Cimetidine, isoniazid, or other CYP450 inhibitors - can raise dapsone plasma concentrations, potentially heightening toxicity.
• Warfarin - dapsone may potentiate anticoagulant effect; monitor INR closely if co-administered.

Because interaction data for Aczone are limited, patients should provide a full medication list-including over-the-counter products and herbal supplements-to their prescriber or pharmacist.

Food and Lifestyle Interactions

• Alcohol - may exacerbate hemolysis; moderate consumption is advised.
• Smoking - can increase methemoglobin levels; patients should be aware of this risk.
• Sun exposure - dapsone does not significantly increase photosensitivity, but a broad-spectrum sunscreen is recommended for all acne patients.

How to Take Aczone

• Standard dose: One 100 mg tablet taken once daily, preferably with a meal to minimise stomach upset.
• Swallow the tablet whole; do not crush or chew it.
• Renal or hepatic impairment: Your doctor may adjust the dose or schedule based on laboratory results.
• Missed dose: Take the missed tablet as soon as you remember unless it is near the time of the next scheduled dose. In that case, skip the missed dose and continue with the regular dosing time. Do not double the dose.
• Overdose: Symptoms may include excessive drowsiness, severe nausea, vomiting, or dark urine. Contact the local poison information service (e.g., NHS 111) or go to the nearest emergency department immediately.
• Discontinuation: Stopping Aczone does not require tapering. However, abrupt cessation may lead to a rebound of acne; discuss a transition plan with your prescriber if you wish to stop.

Monitoring and Follow-Up

Because dapsone can affect blood cells and liver function, the following monitoring schedule is recommended:

• Baseline tests before starting therapy:
• Complete blood count (CBC) with differential
• Liver function panel (ALT, AST, bilirubin)
• G6PD screening
• Follow-up labs:
• CBC at 2 weeks, then monthly for the first 3 months, and thereafter as clinically indicated.
• Liver function tests at 1 month and then periodically if abnormalities arise.
• Clinical assessment:
• Evaluate acne response after 4-6 weeks.
• Monitor for signs of hemolysis (jaundice, dark urine) or infection (fever, sore throat).

If any laboratory values fall outside normal ranges, your healthcare provider may reduce the dose, pause treatment, or discontinue Aczone.

Storage and Handling

• Store tablets at room temperature (15-25 °C), away from moisture and direct sunlight.
• Keep the bottle tightly closed and out of reach of children and pets.
• Do not use tablets after the printed expiry date.
• If disposal is required, return unused medication to a pharmacy waste program; do not flush or discard in household trash.

Medication-Specific Glossary

Methemoglobinemia

A condition in which iron in hemoglobin is oxidised, reducing its ability to bind oxygen and leading to cyanosis and shortness of breath.

G6PD deficiency

An inherited enzyme disorder that makes red blood cells vulnerable to oxidative stress, increasing the risk of hemolysis when exposed to certain drugs, including dapsone.

Agranulocytosis

A severe drop in neutrophil count that compromises the immune system, raising susceptibility to infections.

Hemolytic anemia

Rapid destruction of red blood cells, resulting in fatigue, pallor, and dark urine; can be precipitated by dapsone in susceptible individuals.

Medical Disclaimer

This article provides educational information about Aczone and is not a substitute for professional medical advice. Treatment decisions, including the use of any unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.